Drugs for Movement Disorders - Kruse Flashcards
1
Q
T1/2: Bromocriptine
A
15 h
2
Q
Peak [plasma]: bromocriptine
A
1-3 h
3
Q
metabolism: bromocriptine
A
CYP3A4 - extensive first pass
4
Q
benefit of dopamine antagonist
A
lower incidence of response fluctuations and dyskinesia in comparison to LT L-dopa tx
5
Q
MOA: Pramipexole
A
D3 receptor agonist
6
Q
Tx; Pramipexole
A
RLS
7
Q
peak [plasma]: pramixole
A
2h
8
Q
T1/2: pramipexole
A
8h
9
Q
ROE: pramipexole
A
90% in urine
10
Q
MOA: ropinirole
A
D2 receptor agonist
11
Q
tx: ropinirole
A
RLS
12
Q
Met: ropinirole
A
primarily CYP1A2
13
Q
T1/2: ropinirole
A
6h
14
Q
peak [plasma]: ropinirole
A
1-2h
15
Q
Dopamine receptor agonists
A
- bromocriptine
- pramipexole
- ropinirole
16
Q
AEs: Dopamine Agonists
A
- GI: anorexia, nausea, vomiting
- postural hypotenstion
- peripheral edema + cardiac arrhythmias = stop using
- more severe mental dist than w/ L-dopa
17
Q
CIs: Dopamine agonists
A
- psychosis
- recent MI
- active peptic ulcers
- periperal vascular dz (bromocriptine)